CIRM Selects ALS Research for $2.3 million in Candidate Drug Development

The California Institute for Regenerative Medicine (CIRM), a California stem cell research funding agency, has awarded over $41 million to researchers at California-based universities and companies developing new therapies for difficult diseases, such as muscular dystrophy and Huntington’s Disease. Among the new awardees is Dr. Steven Finkbeiner of the Gladstone Institutes in San Francisco, who was awarded $2.3 million to support his work on a new drug to treat ALS. The drug stimulates the nervous system to protect itself by removing disease-causing proteins. The class of drugs that Finkbeiner is studying is already approved by the Food and Drug Administration for other purposes, making it more likely that a new application to ALS would allow the drug to proceed quickly to clinical trials.

For more on the CIRM awards and Feinkbeiner’s work, click here.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail